Physician profile
James E Nanney
NPI 1558454512
$3,928.59
in general payments reported to CMS, 2019-2025
28 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $716 · 2023: $945 · 2024: $793 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.39 | 2021-2025 | |
| Pfizer INC. | $445.41 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $352.81 | 2021-2025 | Spravato, Xarelto |
| Novo Nordisk INC | $231.91 | 2023-2025 | Rybelsus, Wegovy |
| Lilly USA, LLC | $231.88 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $212.67 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.99 | 2022-2025 | Caplyta |
| Amgen INC. | $165.84 | 2022-2025 | Otezla, Repatha, Repatha |
| Amneal Pharmaceuticals LLC | $121.97 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $119.49 | 2022-2025 | Zoryve, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.85 | 2021-2024 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $70.22 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $67.58 | 2021-2022 | |
| Abbott Laboratories | $55.04 | 2021-2023 | Freestyle Libre 3 |
| Verona Pharma, INC. | $53.26 | 2025 | Ohtuvayre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $50.21 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $48.06 | 2023-2025 | Cologuard Collection Kit |
| Acerus Pharmaceuticals Corporation | $43.55 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.38 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $29.41 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $19.58 | 2025 | Tlando |
| E.R. Squibb & Sons, L.L.C. | $16.49 | 2024 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $16.13 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.04 | 2024 | |
| Lundbeck LLC | $14.55 | 2025 | Rexulti |
| Antares Pharma, INC. | $13.96 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.76 | 2022 | |
| Amarin Pharma, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Nanney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.